SCHEMBL20098569

SCHEMBL20098569

O=C(OCc1ccccc1)c1nc(C(F)(F)F)sc1N1CCOCC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 4/20 0.45
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ PTGDR2 Q9Y5Y4 1/20 0.38
▸ PTGS2 P35354 3/20 0.37
▸ MAPT P10636 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ PRKDC P78527 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ FBP1 P09467 1/20 0.35
▸ TRPV4 Q9HBA0 1/20 0.35
▸ PKM P14618 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18394446 0.80 F10 (0.35) F10PTGS2
SCHEMBL18412939 0.77 F10 (0.34) F10PTGS2
SCHEMBL18394865 0.77 F10 (0.38) F10PTGS2MAPTKDM4EALDH1A1
SCHEMBL20098572 0.73 KMT2A (0.44) MEN1KMT2APTGDR2MAPTKDM4E
SCHEMBL20098694 0.72 F10 (0.34) F10MEN1KMT2APTGS2MAPT
SCHEMBL2178470 0.66 F10 (0.73) F10PTGS2MAPTMAOBPRKDC
SCHEMBL12027626 0.65 MEN1 (0.52) F10MEN1KMT2ANPSR1MAPT
SCHEMBL15201849 0.64 F10 (0.56) F10MEN1KMT2ANPSR1PRKDC
SCHEMBL20866758 0.63 PIK3CA (0.39) MAPTKDM4EALDH1A1GAA
SCHEMBL15110433 0.63 MEN1 (0.50) F10MEN1KMT2ANPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3324977-B1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2022-07-13 — — EP disclosed
US-10881666-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-01-05 — — US disclosed
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-12-15 — — US disclosed
US-20200223867-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2020-07-16 — — US disclosed
US-10570153-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-02-25 — — US disclosed
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-06-27 — — US disclosed
WO-2019067864-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-04-04 — — WO disclosed
US-9957281-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2018-05-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 F10 1867/4885MEN1 3463/4885KMT2A 1493/4885
US-10881666-B2 Combination pharmaceutical agents as RSV inhibitors SERPINB1, FURIN, HIF1AN F10 1034/4885MEN1 3503/4885KMT2A 3794/4885
US-10570153-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 F10 1867/4885MEN1 3463/4885KMT2A 1493/4885
US-20200223867-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 F10 1867/4885MEN1 3463/4885KMT2A 1493/4885
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS SERPINB1, FURIN, HIF1AN F10 1034/4885MEN1 3503/4885KMT2A 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback